Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 15/20 | 0.50 |
| ▸ | RIPK2 | O43353 | 12/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | BIRC3 | Q13489 | 3/20 | 0.46 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lcl-161 SCHEMBL1275554 | 1.00 | XIAP (0.50) | XIAPRIPK2ESR1BIRC3BIRC2 | |
| Lcl-161 SCHEMBL1275369 | 1.00 | XIAP (0.50) | XIAPRIPK2ESR1BIRC3BIRC2 | |
| Lcl-161 SCHEMBL19164873 | 1.00 | XIAP (0.50) | XIAPRIPK2ESR1BIRC3BIRC2 | |
| Lcl-161 SCHEMBL1275371 | 1.00 | XIAP (0.50) | XIAPRIPK2ESR1BIRC3BIRC2 | |
| Lcl-161 SCHEMBL18663754 | 1.00 | XIAP (0.50) | XIAPRIPK2ESR1BIRC3BIRC2 | |
| Lcl-161 SCHEMBL1495180 | 1.00 | XIAP (0.50) | XIAPRIPK2ESR1BIRC3BIRC2 | |
| Lcl-161 SCHEMBL3688581 | 1.00 | XIAP (0.50) | XIAPRIPK2ESR1BIRC3BIRC2 | |
| SCHEMBL23975497 | 0.98 | XIAP (0.49) | XIAPRIPK2ESR1BIRC3BIRC2 | |
| SCHEMBL23975269 | 0.98 | XIAP (0.49) | XIAPRIPK2ESR1BIRC3BIRC2 | |
| SCHEMBL23975195 | 0.98 | XIAP (0.49) | XIAPRIPK2ESR1BIRC3BIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2296650-B1 | IMMUNOMODULATION BY IAP INHIBITORS | NOVARTIS AG (CH) | 2020-05-06 | — | — | EP | claimed |
| US-10329626-B2 | NOL3 is a predictor of patient outcome | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-25 | — | — | US | claimed |
| CN-101588801-B | Combination of IAP inhibitors and FLT3 inhibitors | NOVARTIS AG (CH) | 2011-12-28 | — | — | CN | claimed |
| US-10975114-B2 | Bis 2′-5′-RR-(3′F-A)(3′F-A) cyclic dinucleotide compound and uses thereof | CHINOOK THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| CN-111989338-A | Modified cyclic dinucleotide compounds | 勃林格殷格翰国际有限公司 | 2020-11-24 | — | — | CN | disclosed |
| US-20200199169-A1 | BIS 2'-5'-RR-(3'F-A)(3'F-A) CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2020-06-25 | — | — | US | disclosed |
| EP-3116909-B1 | ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF | NOVARTIS AG (CH) | 2019-11-13 | — | — | EP | disclosed |
| CN-101588801-B | Combination of IAP inhibitors and FLT3 inhibitors | NOVARTIS AG (CH) | 2011-12-28 | — | — | CN | disclosed |
| CN-101588801-A | Combination of IAP inhibitors and FLT3 inhibitors | NOVARTIS AG (CH) | 2009-11-25 | — | — | CN | disclosed |
| CN-101541325-A | Use of IAP inhibitors for the treatment of acute myeloid leukemia | NOVARTIS AG (CH) | 2009-09-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199169-A1 | BIS 2'-5'-RR-(3'F-A)(3'F-A) CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF | STING1, IRF3, IFNAR1 | XIAP 1037/4885RIPK2 1070/4885ESR1 2028/4885 |
| US-10329626-B2 | NOL3 is a predictor of patient outcome | MORF4L1, NOS3, NOS1 | XIAP 1033/4885RIPK2 3353/4885ESR1 3116/4885 |
| US-10975114-B2 | Bis 2′-5′-RR-(3′F-A)(3′F-A) cyclic dinucleotide compound and uses thereof | STING1, IRF3, IFNAR1 | XIAP 1045/4885RIPK2 1061/4885ESR1 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.